ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) as of 5:00 P.M. on September 9, 2024. The notice pertains to Form S-3, which is commonly used by companies to register securities for potential future offerings. This development indicates that ZyVersa Therapeutics has met the necessary regulatory requirements to move forward with the registration of its securities, as documented under file number 333-281913. The effectiveness of the form is a crucial step for the company, potentially paving the way for future capital raising activities through the sale of registered securities.

ZyVersa Therapeutics, Inc., a biopharmaceutical company, has achieved a significant milestone with the Notice of Effectiveness from the United States Securities and Exchange Commission (SEC) as of 5:00 P.M. on September 9, 2024. The notice pertains to Form S-3, which is commonly used by companies to register securities for potential future offerings. This development indicates that ZyVersa Therapeutics has met the necessary regulatory requirements to move forward with the registration of its securities, as documented under file number 333-281913. The effectiveness of the form is a crucial step for the company, potentially paving the way for future capital raising activities through the sale of registered securities.